[Federal Register Volume 84, Number 241 (Monday, December 16, 2019)]
[Notices]
[Page 68474]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-27095]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-560]


Importer of Controlled Substances Application: Novitium Pharma 
LLC

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before January 15, 2020. 
Such persons may also file a written request for a hearing on the 
application on or before January 15, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: 
    In accordance with 21 CFR 1301.34(a), this is notice that on July 
18, 2018, Novitium Pharma, LLC., 70 Lake Drive, East Windsor, New 
Jersey 08520 applied to be registered as an importer of the following 
basic class of controlled substance:

------------------------------------------------------------------------
         Controlled substance           Drug code         Schedule
------------------------------------------------------------------------
Levorphanol...........................       9220  II
------------------------------------------------------------------------

    The company plans to import the controlled substance to develop the 
manufacturing process for a drug product that will in turn be used to 
produce a tablet equivalent to the current brand product.

    Dated: December 3, 2019.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2019-27095 Filed 12-13-19; 8:45 am]
BILLING CODE 4410-09-P